Compare YSS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSS | ERAS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | 710 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | N/A | 2021 |
| Metric | YSS | ERAS |
|---|---|---|
| Price | $20.52 | $19.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $36.56 | $14.25 |
| AVG Volume (30 Days) | 1.6M | ★ 5.5M |
| Earning Date | 03-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $48.43 | N/A |
| Revenue Next Year | $52.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.93 | $1.33 |
| 52 Week High | $44.54 | $24.28 |
| Indicator | YSS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 35.01 | 73.23 |
| Support Level | $20.31 | $12.36 |
| Resistance Level | $36.36 | $24.28 |
| Average True Range (ATR) | 2.59 | 1.21 |
| MACD | -0.57 | 0.32 |
| Stochastic Oscillator | 6.25 | 90.66 |
York Space Systems Inc is a U.S.-based space and defense company that provides mission-related solutions for national security, government, and commercial customers. The company develops its own hardware and software, offering capabilities intended to support customer requirements across various elements of the space mission lifecycle. It offers mission solutions across several complementary product categories: Components, Subsystems, Spacecraft Platforms, Ground Operation, Global Downlink, and Software-Enabled Services. The company derives the majority of revenue from long-term firm-fixed-price (FFP) production contracts for the design of small satellites, launch services, and ground services with both U.S. federal government-controlled agencies and domestic commercial customers.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.